VERO - Venus Concept Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.02 (+0.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.63
Bid3.00 x 1000
Ask7.00 x 800
Day's Range5.40 - 5.90
52 Week Range2.63 - 23.25
Avg. Volume75,633
Market Cap167.622M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • GlobeNewswire

    Venus Concept Announces Preliminary Fourth Quarter and Fiscal Year 2019 Revenue Results; Introduces Fiscal Year 2020 Revenue Guidance

    Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced preliminary unaudited revenue results for the three months and twelve months ended December 31, 2019 and introduced revenue guidance expectations for the twelve months ended December 31, 2020. The Company notes that the GAAP revenue results provided give effect to the business combination between Restoration Robotics, Inc. and Venus Concept Ltd., which closed on November 7, 2019. Preliminary total GAAP revenue for the fourth quarter of 2019 is expected to be in the range of $31.3 million to $32.0 million, compared to total GAAP revenue of $28.6 million in fourth quarter 2018, an increase of 9% to 12% year-over-year.

  • GlobeNewswire

    Venus Concept Inc. Announces CE Mark and Australian Regulatory Approval for NeoGraft 2.0, A Trusted Name in Hair Restoration

    Venus Concept Inc. (“Venus Concept” or the “Company”) (VERO), a global medical aesthetic technology leader, today announced that it has received a CE Mark from DEKRA Certification B.V. and Therapeutic Goods Administration (TGA) clearance in Australia to market NeoGraft 2.0 for hair restoration. NeoGraft 2.0 is intended as an automated hair transplant device using the Follicular Unit Extraction (FUE) method of harvesting and implanting hair follicles. With the introduction of NeoGraft 2.0, Venus Concept has eliminated the inefficiencies of manual extractions and implants and replaced it with advanced technology that provides patients with the benefits of the FUE procedure, while also enabling physicians to benefit from easier transplants that yield superior clinical results.